Navigation Links
European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease
Date:3/31/2011

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

Wilson disease is a rare genetic storage disorder in which copper is not excreted by the body effectively, leading to excess copper build up, liver failure and damage to the brain (neurological problems). Worldwide the condition, affects approximately one in 30,000 people. If not treated, Wilson disease can be chronically debilitating and life threatening. While current guidelines recommend the use of chelating agents (D-penicillamine, trientine) as first line therapy of symptomatic patients, optimal treatment regimens are yet to be established.

In this retrospective multicentre cohort study the long-term outcomes of treatment with D-penicillamine and trientine were reviewed in 347 patients with the condition. Changes of medication were common in both groups and resulted in a total of 467 analysed treatments (D-penicillamine, n=326, trientine n=141). Following an average follow-up of 16.5 years, both treatments provided a similar and excellent survival rate and prevented disease progression with the need for liver transplantation in over 98% of patients.

Daniele Prati, EASL's Scientific Committee Member and Press Committee Chairman commented: "Not only does this study show that both treatments are effective options for patients with this rare and often debilitating condition, but it is also encouraging to see how European countries can work together and exchange data which is extremely valuable to guide best practice and evaluate existing treatment regimens. Research on rare liver diseases presents remarkable interest."

"To date, a very limited number of drugs for these conditions are marketed, leaving the majority of rare diseases w
'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-790-013-8904
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related biology news :

1. UC Riverside researcher receives $9 million USDA grant to study potato and tomato disease
2. New study shows you can have your candy and eat it too -- without adverse health effects
3. Study: Emissions trading doesnt cause pollution hot spots
4. Butterfly study reveals traits and genes associated with establishment of new populations
5. Study shows hunger hitting closer to home
6. Most states unclear about storage, use of babies blood samples, new study finds
7. GPS study shows wolves more reliant on a cattle diet
8. Russian boreal forests undergoing vegetation change, study shows
9. Spicing up your love life possible, study finds
10. Study finds weight training safe for pregnant women
11. Study predicts large regional changes in farmland area
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... , NORWOOD, Mass. , ... metabolomics company developing novel clinical diagnostic tools for applications in personalized ... Series B financing. New investor Atlas Venture ( Waltham, MA ) ... ( Wayne, PA ), and Oxford Bioscience Partners ( Boston, MA ...
... number of scientists are merging methods and results from different ... team of researchers in a recent issue of Evolution ... new data, however, researchers who want to analyze previous findings ... the authors say. In a commentary piece in the journal ...
... fortuita , new to the Iberian Peninsula and to science. ... is also a new entry for Europe and is the ... Foliicolous lichens, symbiosis between fungi and algae, are organisms ... environments such as the Iberian Peninsula, outside of the tropics, ...
Cached Biology News:Molecular Biometrics Closes $12.5 Million Series B Equity Funding 2Molecular Biometrics Closes $12.5 Million Series B Equity Funding 3Molecular Biometrics Closes $12.5 Million Series B Equity Funding 4Molecular Biometrics Closes $12.5 Million Series B Equity Funding 5Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3A new species of lichen discovered in the Iberian Peninsula 2
(Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
(Date:2/26/2015)... 26, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... skin and hair rejuvenation, has announced that it ... record for investor relations and strategic communications. ... sales and diversification strategies – and we need ... shareholders," stated Ali Kharazmi CEO of NuGene when ...
(Date:2/26/2015)... February 26, 2015 Already well respected ... line by expanding its Length Gauge offerings with new ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length ... specification. Two new 1Vpp, 12mm stroke length variants ... applications. One is a variant with a weak spring, ...
(Date:2/26/2015)... Feb. 26, 2015  Dyadic International, Inc. ("Dyadic") ... and proprietary technologies are used to develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... results for year ending December 31, 2014 after ... will host a conference call that day at ...
Breaking Biology Technology:Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3
... PRINCETON, N.J., June 8 Celator Pharmaceuticals today ... the extended therapeutic bioavailability and tumor cell selectivity ... presented at the 14th Congress of the European ... 2009 (Abstracts 1398 and 383). , , ...
... BEIJING, June 8 /PRNewswire-Asia-FirstCall/ ... "Yongye" or the "Company"), a,leading developer and distributor ... in the People,s Republic of China (PRC), today,announced ... Yongye,Nongfeng Biotechnology Co., Ltd. (,Yongye Nongfeng,), it has ...
... in US dollars , , QUEBEC CITY, June ... AEZS ; TSX: AEZ), a global biopharmaceutical company focused ... regaining from Ardana Biosciences Ltd. ("Ardana"), the worldwide rights ... AEZS-130, it has entered into an agreement with the ...
Cached Biology Technology:Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 2Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 3Yongye Biotechnology International Receives License to Manufacture Products 2Yongye Biotechnology International Receives License to Manufacture Products 3AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 2AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 3
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,382-1) ... assistance. ID clarifier: barcoded Mfr ...
... Optically clear dishes with stacking feature for ... new product number, created to easily match Cornings ... order under the old Sigma-Aldrich number (Z70,947-6) or ... low binding surface Comp Dim: surface area 55 ...
... ,Kit containing Dermal Fibroblasts (Mouse/BalbC) and media. ... long-term culture, and is guaranteed to provide ... from the date supplied, when used with ... embryonic day 18.5 ,Applications: ,Cultivation: ...
...
Biology Products: